TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How can serial MRD monitoring be utilized to improve relapse outcomes?

Featured:

Nicholas J. ShortNicholas J. Short

Dec 27, 2022


During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Nicholas Short, MD Anderson Cancer Centre, US. We asked, How can serial minimal residual disease (MRD) monitoring be utilized to improve relapse outcomes?

How can serial MRD monitoring be utilized to improve relapse outcomes?

Short discusses the prognostic value of MRD and the impact of MRD recurrence in patients with acute myeloid leukemia who have previously achieved MRD-negative remission. This is followed by a discussion of the clinical rarity of detecting MRD recurrence and the poor outcomes seen in these patients compared with those with persistent MRD negativity. Short concludes by describing the benefit of serial monitoring of MRD to identify these high-risk patients.

More about...

Your opinion matters

Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?